Scientists tested an experimental CRISPR-based drug that helped keep blood fat levels reduced in monkeys for three years after a single dose. Specifically, triglyceride levels fell by an average of 43%, while “bad” cholesterol dropped by 13%. The study results were published in the journal Nature.

The drug targets the ANGPTL3 gene, which is responsible for the liver’s production of a protein that slows the removal of fats from the blood. Using CRISPR, the researchers changed a single letter in the DNA, disrupting the gene’s function. As a result, the liver produced significantly less ANGPTL3 protein.

The experiment involved ten monkeys that received a single infusion of the drug. Three years later, their levels of this protein remained an average of 94% below baseline, while triglyceride levels were 43% lower. LDL cholesterol fell by about 13%.

The researchers also tested the drug in four monkeys with an LDL receptor deficiency—a defect also seen in a severe inherited form of high cholesterol. Over 35 days, the animals’ “bad” cholesterol levels fell from an average of 458 to 247 mg/dL, a reduction of 46%. However, the long-term effect in this group has not yet been studied.

The animals’ liver enzyme levels rose temporarily but returned to baseline within two weeks. However, experiments in monkeys cannot definitively establish the method’s safety in humans.

The human version of the drug, VERVE-201, is already undergoing Phase 1 clinical trials. Scientists still need to determine how safe and effective this type of DNA editing is in humans. In the future, a one-time procedure could offer an alternative to ongoing medication to lower cholesterol and triglyceride levels.